La vendita allo scoperto per Merck & Co dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Merck & Co. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Merck & Co (NYSE:MRK) Azioni, Report sulle vendite allo scoperto

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Long Ideas

News

Markets

Media

Trading Ideas

ENVA

FTNT

GEHC

PANW

TDOC

Jim Cramer si dice deluso per aver scelto GE HealthCare come la peggiore delle tre azioni. Ecco che cosa è successo.

Jim Cramer desolato: ha comprato la &#34;peggiore delle tre&#34;

Merck & Co Inc

Marker Therapeutics Inc

Merck (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session&#39;s end. This change lagged the S&amp;P 500&#39;s daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%.
The pharmaceutical company&#39;s shares have seen a decrease of 2.27% over the last month, aligning with the Medical sector and falling behind the S&amp;P 500&#39;s gain of 1.71%.
Market participants will be closely following the financial results of Merck in its upcoming release. The company plans to announce its earnings on October 31, 2024. The company is forecasted to report an EPS of $1.77, showcasing a 16.9% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.48 billion, up 3.24% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $8.01 per share and a revenue of $64.14 billion, demonstrating changes of +430.46% and +6.69%, respectively, from the preceding year.
It&#39;s also important for investors to be aware of any recent modifications to analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company&#39;s business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Merck possesses a Zacks Rank of #4 (Sell).
Looking at its valuation, Merck is holding a Forward P/E ratio of 14.33. This valuation marks a discount compared to its industry&#39;s average Forward P/E of 15.78.
We can additionally observe that MRK currently boasts a PEG ratio of 1.59. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company&#39;s projected earnings growth. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.67.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 44, this industry ranks in the top 18% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
<a href="https://www.zacks.com/stock/news/2342265/merck-mrk-stock-sinks-as-market-gains-here-s-why?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-2342265">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Analyst Ratings

Merck Stock Sinks As Market Gains: Here's Why

Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) inked an option and licensing deal with Merck &amp; Co., Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for two <a href="https://www.benzinga.com/pressreleases/24/09/g41043464/evaxion-significantly-expands-vaccine-development-collaboration-with-msd" target="_blank" rel="noreferrer noopener">preclinical vaccine candidates</a>.
Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 and EVX-B3.
EVX-B2 is a protein-based candidate for Gonorrhea, and EVX-B3 targets an undisclosed infectious agent.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36765592/why-is-cancer-therapy-focused-evaxion-biotech-stock-trading-higher-today" rel="noreferrer noopener">Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?</a>
Evaxion will receive an upfront payment of $3.2 million and up to $10 million in 2025 as part of the deal. The agreement is contingent upon Merck exercising its option to license either one or both candidates.
In addition, Evaxion is eligible for development, regulatory, and sales milestone payments with a potential value of up to $592 million per product, and royalties on net sales.
Christian Kanstrup, CEO of Evaxion, called the collaboration &#8220;transformative&#8221; and a &#8220;strong validation&#8221; of the company&#8217;s AI-Immunology platform and vaccine candidates. 
Evaxion and Merck have been collaborating on EVX-B3 since 2023. At the time, Merck, through its Global Health Innovation Fund (MGHIF), led a private placement round of financing for Evaxion to become the company&#8217;s single largest shareholder.
MGHIF also participated in Evaxion&#8217;s public offering in February this year.
Last year, Evaxion Biotech collaborated with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion&#8217;s EDEN-<a href="https://www.benzinga.com/general/biotech/23/09/34768492/why-is-cancer-immunotherapy-focused-evaxion-biotech-stock-trading-higher-today" target="_blank" rel="noreferrer noopener">discovered gonorrhea targets</a>.
Price Action: EVAX stock is up 8.83% at $3.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41044267/exclusive-srivarus-prana-2-0-electric-motorcycle-earns-key-indian-certification" target="_blank" rel="noreferrer noopener">EXCLUSIVE: SRIVARU&#8217;s PRANA 2.0 Electric Motorcycle Earns Key Indian Certification</a></li>
</ul>
Image: Courtesy of Merck

Biotech

Health Care

Contracts

Movers

General

EVAX

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Under the terms of the agreement, Evaxion has granted MSD an option to exclusively license Evaxion's preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea and EVX-B3 targets an undisclosed infectious agent.

Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product

Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress

Financial giants have made a conspicuous bullish move on Merck &amp; Co. Our analysis of options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $119,340, and 5 were calls, valued at $224,086.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $120.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 2075.86, with a total volume reaching 6,696.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $100.0 to $120.0, throughout the last 30 days.
<h3>Merck &amp; Co Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727297131_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.0</td>
<td>$9.85</td>
<td>$9.85</td>
<td>$120.00</td>
<td>$58.1K</td>
<td>1.2K</td>
<td>60</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$24.5</td>
<td>$20.0</td>
<td>$21.9</td>
<td>$100.00</td>
<td>$56.9K</td>
<td>318</td>
<td>26</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.99</td>
<td>$0.95</td>
<td>$0.95</td>
<td>$118.00</td>
<td>$44.4K</td>
<td>972</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.9</td>
<td>$0.88</td>
<td>$0.9</td>
<td>$118.00</td>
<td>$36.9K</td>
<td>972</td>
<td>2.8K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.35</td>
<td>$3.2</td>
<td>$3.35</td>
<td>$118.00</td>
<td>$34.8K</td>
<td>16</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
After a thorough review of the options trading surrounding Merck &amp; Co, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>With a volume of 7,899,351, the price of MRK is down -0.1% at $114.84. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What Analysts Are Saying About Merck &amp; Co</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $155.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $155. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On Merck & Co

On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and esophageal <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">squamous cell carcinoma</a>.
The FDA <a target="_blank" href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024" rel="noreferrer noopener">notes</a> that the current labeling for approved checkpoint inhibitors in this indication reflects broad approvals in the intent to treat patient populations agnostic of programmed death cell ligand-1 (PD-L1) expression.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer</a>.
Cumulative data has shown that PD-L1 expression appears to be a predictive biomarker of treatment efficacy in this patient population; however, clinical trials have used different approaches to assess PD-L1 expression and different thresholds to define PD-L1 positivity.
The review includes existing approvals for&nbsp;Bristol Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Opdivo (nivolumab) and Yervoy (ipilimumab),&nbsp;Merck &amp; Co Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)&nbsp;Keytruda (pembrolizumab), and pending applications for&nbsp;BeiGene Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)&nbsp;Tevimbra (tislelizumab).
In a&nbsp;<a target="_blank" href="https://www.fda.gov/media/182138/download" rel="noreferrer noopener">briefing document</a>, the FDA indicated that combining immune checkpoint inhibitors (ICIs) with standard chemotherapy does not seem to offer benefits for patients with PD-L1 expression below 1%. Patients with PD-L1 levels of 10% or higher experience the most significant benefit.
The advantages remain unclear for those with PD-L1 levels between 1% and 10%, and interpreting the data is difficult.
Given that patients with low or absent PD-L1 expression are unlikely to benefit, administering anti-PD-1 therapy may introduce risks, including severe immune-related adverse effects, which can further diminish the quality of life in individuals already dealing with malignancy.
"Although these results are exploratory &#8230; strong evidence does not appear to support the use of anti-PD-L1 drugs in patients with low PD-L1 expression," the FDA <a target="_blank" href="https://www.fda.gov/media/182143/download" rel="noreferrer noopener">said</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma" target="_blank" rel="noreferrer noopener">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>.</li>
</ul>
Image by PDPics from Pixabay

BGNE

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed new long-term results on Wednesday, showing promise for treatment in patients with <a href="https://www.benzinga.com/general/biotech/24/09/40884197/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss">moderate-to-severe atopic dermatitis</a>. 
What Happened: The company&#8217;s data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV).
The EADV is a leading professional society focused on the fields of dermatology and venereology.
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke" rel="noreferrer noopener">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a>.
Why It Matters: The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older.
<ul>
<li>84% of the patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin (IGA 0,1) at three years.</li>
<li>87% of the patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.</li>
<li>83% of the patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require high-potency topical corticosteroids or systemic treatments.</li>
</ul>
Those who participated in the study have moderate-to-severe atopic dermatitis (eczema).
The European Union approved Ebglyss in 2023. Japan approved it in January; additional markets are expected to follow suit.
Lilly has exclusive rights for the development and commercialization of Ebglyss in the U.S. and elsewhere outside&nbsp;Europe.
In Europe, Lilly&#8217;s partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.
Price Action: Eli Lilly stock is up 0.17% at $926 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41023437/mercks-experimental-favezelimabkeytruda-combo-fails-in-late-stage-colorectal-cancer-study" target="_blank" rel="noreferrer noopener">Merck&#8217;s Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study</a></li>
</ul>
Image: Shutterstock

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years

On Wednesday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41020856/merck-provides-update-on-phase-3-keyform-007-trial-evaluating-investigational-fixed-dose-combinati" rel="noreferrer noopener">colorectal cancer (mCRC)</a>.
The US drug giant said the study did not meet its primary endpoint of overall survival.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40926567/mercks-keytruda-secures-first-fda-approval-for-rare-form-aggressive-cancer" rel="noreferrer noopener">Merck&#8217;s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer</a>.
At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not demonstrate an improvement in OS compared to standard of care (regorafenib or TAS-102 [trifluridine and tipiracil hydrochloride]).
The safety profile of the fixed-dose combination was consistent with that observed for favezelimab and pembrolizumab in previously reported studies, with no new safety signals observed.
A full data evaluation is ongoing.
In the U.S., Keytruda is approved for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Keytruda has not been approved for the treatment of MSS mCRC.
Last month, Merck stopped two Keytruda Phase 3 trials, KEYNOTE-867&nbsp;and KEYNOTE-630, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data" rel="noreferrer noopener">after underwhelming data</a>.
Concurrently, on Wednesday, Japan&#8217;s drug regulator approved new indications for Keytruda (pembrolizumab), in certain <a href="https://www.benzinga.com/pressreleases/24/09/b41020647/mercks-keytruda-pembrolizumab-receives-new-approvals-in-japan-for-certain-patients-with-non-small-" target="_blank" rel="noreferrer noopener">lung and urothelial cancers</a>.
<h2 class="wp-block-heading">Merck Stock Prediction For 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Merck &amp; Co have an average 1-year price target of $142.57, representing an expected upside of 24.02%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Merck &amp; Co, while 5 analysts have bullish ratings. The street high price target from Cantor Fitzgerald is $155.0, while the street low from Wells Fargo is $125.0.
Price Action: MRK stock is down 0.10% at $114.85 during the premarket session at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41021010/vertex-energy-files-for-chapter-11-bankruptcy-secures-80m-lifeline-financing" target="_blank" rel="noreferrer noopener">Vertex Energy Files For Chapter 11 Bankruptcy, Secures $80M Lifeline Financing</a>.</li>
</ul>
Photo Courtesy of Merck

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

Merck Says Phase 3 KEYFORM-007 Trial Of Fixed-dose Combination Of Favezelimab And Keytruda (Pembrolizumab) Did Not Meet Its Primary Endpoint Of Overall Survival For Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

<ul>
<li>KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment, for patients with non-small cell lung carcinoma (NSCLC) based on results from the Phase 3 KEYNOTE-671 trial;</li>
<li>KEYTRUDA in combination with Padcev (enfortumab vedotin-ejfv) for the first-line treatment of patients with radically unresectable urothelial carcinoma based on results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in a research collaboration with Pfizer (previously Seagen) and Astellas;</li>
<li>KEYTRUDA monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy based on results from the Phase 2 KEYNOTE-052 trial.</li>
</ul>

The Japanese Ministry Of Health, Labor And Welfare Has Approved New Indications For Merck's Keytruda (Pembrolizumab) In Certain Lung And Urothelial Cancers

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases

Merck Animal Health Announces Expansion Of NOBIVAC NXT Platform With First And Only RNA-Particle Technology Vaccine For Feline Leukemia Virus

Deep-pocketed investors have adopted a bearish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 2 are puts, totaling $84,071, and 9 are calls, amounting to $500,344.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $125.0 for Merck &amp; Co, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 3469.29, with a total volume reaching 7,958.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $110.0 to $125.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727118928_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.74</td>
<td>$1.65</td>
<td>$1.68</td>
<td>$117.00</td>
<td>$120.4K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.77</td>
<td>$2.72</td>
<td>$2.72</td>
<td>$120.00</td>
<td>$98.3K</td>
<td>4.8K</td>
<td>64</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.76</td>
<td>$0.72</td>
<td>$0.75</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>9.8K</td>
<td>998</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.95</td>
<td>$9.85</td>
<td>$9.89</td>
<td>$115.00</td>
<td>$49.4K</td>
<td>298</td>
<td>4</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.0</td>
<td>$2.98</td>
<td>$2.98</td>
<td>$115.00</td>
<td>$45.2K</td>
<td>4.5K</td>
<td>468</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a trading volume of 3,262,924, the price of MRK is down by -1.08%, reaching $115.9.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 38 days from now.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $155.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $155. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Merck & Co Unusual Options Activity For September 23

On Saturday, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) presented positive trial data for experimental drug designed for patients suffering from&nbsp;cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as&nbsp;9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight.
<h3>Paving The Way For The World&rsquo;s First Treatment For Cancer Cachexia</h3>
The mid-stage trial results showed that patients that were treated with the experimental drug that Pfizer developed showed improvements in body weight, muscle mass, quality of life and physical function. Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically&nbsp;for this condition. This would translate to Pfizer saving many lives as 80% of cancer patients who suffer from this condition are not expected to make it beyond a year of being diagnosed as they are unable to meet their body&rsquo;s energy and nutritional needs. The condition also makes the general treatment of cancer less effective and lowers the odds of survival as it leaves the patient even weaker, unable to tolerate the treatment.&nbsp;
<h3>The Trial</h3>
Involving&nbsp;187 patients diagnosed with non-small cell lung cancer, pancreatic cancer or colorectal cancer and high levels of a key driver of cachexia, patients who took the highest dose of ponsegromab, which is 400 milligrams, over the course of 12 weeks&nbsp;observed a&nbsp;5.6% increase in weight compared to those patients who received a placebo. Patients who took lower doses of 200 or 100-milligrams observed roughly 3.5% and 2% increase in body weight compared to the placebo group. Pfizer added that experts consider weight gain greater than 5% as a &ldquo;clinically meaningful difference&rdquo; when it comes to cancer patients with cachexia and noted that increased appetite and improvement in physical activity is what was most encouraging.&nbsp;&nbsp;The good news is that no significant side effects of the drug were observed. Pfizer is planning to begin late-stage development studies in 2025 that can be used to file for approval, while also studying the effect of ponsegromab in a phase two trial in patients diagnosed with heart failure.
Catching up to Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) and others on the cancer front.
It&rsquo;s no secret that Pfizer has turned to oncology in an effort to combat the Covid-19 decline.&nbsp;&nbsp;To turn its business around, it targeted as many as 8 blockbuster cancer drugs by the end of this decade. One of its main Covid-19 rivals, Moderna is expected to launch its experimental cancer vaccine as early as next year.
Together with Merck &amp; Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>), Moderna is currently testing their combined treatment for advanced melanoma in a large-scale Phase III trial. Approximately, 1,089 patients at more than 165 sites across the globe will be tested to assess the efficiency of the experimental vaccine mRNA-4157 that Moderna and Merck co-developed, along with the immunotherapy drug, Keytruda, that is already a blockbuster for Merck. The study will assess the efficiency of the treatment that Moderna and Merck created in achieving a recurrence-free survival, while the secondary endpoints are distant metastasis-free survival, along with overall survival and safety.
&nbsp;
Codenamed mRNA-4359, Moderna also designed a vaccine to boost people&#39;s immunity to better recognize and fight a variety of advanced solid tumor cancers. During the above-mentioned congress that took place in Barcelona, Spain, on Saturday, researchers at King&rsquo;s College London&nbsp;presented&nbsp;Phase I/II trial to test Moderna&rsquo;s vaccine candidate, more precisely its ability to sensitize the immune system to two specific proteins commonly common in tumor cells as well as other cells that suppress the immune system, PD-L1 and IDO1.&nbsp;From 16 patients diagnosed with advanced lung cancer, melanoma, and other solid tumors who were able to have their responses measured, eight patients showed no signs of their tumors growing and there were no new tumors formed. In addition, tests found that the vaccine seemed to generate a noticeable increase in immune cells that could recognize PD-L1 and IDO1.&nbsp;While more data will be needed to know whether mRNA-4359 can work as hoped, these results are promising.&nbsp;
The future of cancer treatment looks bright.
Besides vaccines designed to help patients combat cancer, Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) advanced on the early screening and prevention front. A molecular genetics diagnostic company specialized in the early detection of cancer,&nbsp;Mainz Biomed is currently seeking FDA approval for its colorectal cancer test, ColoAlert. With an innovative portfolio of mRNA biomarkers, Mainz Biomed is promising to set a new gold standard for noninvasive detection of advanced adenoma, which is a well-known pre-cancerous condition. This week, Mainz Biomed announced its newest Brand Ambassador,&nbsp;Petra Smeltzer Starke, known serving as&nbsp;General Counsel to the White House Council of Economic Advisors and Senior Advisor to President Obama. Ms. Smeltzer Starke&rsquo;s role will be to help to raise awareness on the importance of early detection of colorectal cancer. If diagnosed early, up to 90% of colorectal cancer cases can be treated successfully. Therefore, early screening makes all the difference.&nbsp;
By the looks of it, years ahead seem promising when it comes to revolutionizing cancer treatment.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Penny Stocks

Eurozone

MRNA

MYNZ

Pfizer Advances On Its Cancer Journey

The first opinion recommends the approval of KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy.
The second positive opinion recommends the approval of KEYTRUDA in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.
The CHMP&#39;s recommendations will now be reviewed by the European Commission for marketing authorization in the European Union (EU), and final decisions are expected in the&nbsp;fourth quarter&nbsp;of 2024.

Merck Says European Medicines Agency's CHMP Adopted Positive Opinions Recommending Approval Of Keytruda (Pembrolizumab), Its Anti-PD-1 Therapy, For Two Indications In Gynecologic Cancers

Wednesday, the FDA approved Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40915575/fda-approves-mercks-keytruda-pembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line" rel="noreferrer noopener">malignant pleural mesothelioma (MPM).</a>
The approval marks the first indication for Keytruda in MPM in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40896344/merckdaiichi-sankyo-partnered-lung-cancer-candidate-meets-primary-goal-in-late-stage-study" rel="noreferrer noopener">Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study</a>.
MPM&nbsp;is&nbsp;a rare, aggressive cancer that forms in the lining of the lungs and chest.
The approval is based on pivotal Phase 2/3 IND.227/KEYNOTE-483 trial data.
Keytruda plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS), reducing the risk of death by 21% compared to chemotherapy alone.
Median OS was 17.3 months for Keytruda plus chemotherapy versus 16.1 months for chemotherapy alone.
Keytruda plus chemotherapy also significantly improved progression-free survival (PFS) versus chemotherapy alone.
The overall response rate (ORR) was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%), respectively.
Adverse reactions occurring in patients with MPM were generally similar to those in other patients receiving Keytruda in combination with pemetrexed and platinum chemotherapy.
In August, Merck discontinued two Keytruda <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data" rel="noreferrer noopener">late-stage studies</a>.
<ul>
<li>Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy for stage I or II non-small cell lung cancer, including those who are medically inoperable or <a href="https://www.benzinga.com/pressreleases/24/08/b40621006/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials" target="_blank" rel="noreferrer noopener">have refused surgery</a>.</li>
<li>Phase 3 KEYNOTE-630 trial of Keytruda for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent DMC.</li>
</ul>
Price Action: MRK stock is trading 0.04% higher at $118.34&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/09/40919923/consumer-giant-reckitt-seeks-help-from-investment-banks-to-evaluate-options-for-homecare-brands-baby" target="_blank" rel="noreferrer noopener">Consumer Giant Reckitt Seeks Help From Investment Banks To Evaluate Options For Homecare Brands, Baby Formula</a>.</li>
</ul>

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

Deep-pocketed investors have adopted a bullish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 0% bearish. Among these notable options, 4 are puts, totaling $160,474, and 4 are calls, amounting to $152,824.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $145.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 3342.14, with a total volume reaching 7,571.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $100.0 to $145.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726680732_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$0.2</td>
<td>$0.01</td>
<td>$0.1</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>8.5K</td>
<td>6.5K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.1</td>
<td>$5.05</td>
<td>$5.05</td>
<td>$140.00</td>
<td>$62.1K</td>
<td>195</td>
<td>125</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.53</td>
<td>$1.46</td>
<td>$1.46</td>
<td>$105.00</td>
<td>$42.3K</td>
<td>7.3K</td>
<td>290</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.7</td>
<td>$2.99</td>
<td>$3.5</td>
<td>$135.00</td>
<td>$35.0K</td>
<td>1.5K</td>
<td>100</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$2.65</td>
<td>$2.61</td>
<td>$2.65</td>
<td>$145.00</td>
<td>$28.0K</td>
<td>1</td>
<td>145</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a trading volume of 3,730,655, the price of MRK is up by 0.01%, reaching $118.3.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What The Experts Say On Merck &amp; Co</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $155.0.
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. </li>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Merck &amp; Co, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Merck & Co's Latest Options Trends

The FDA Approves Merck's Keytruda In Combination With Pemetrexed And Platinum Chemotherapy, For The First-line Treatment Of Adult Patients With Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Merck &amp; Co Background</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.84</td>
<td>6.86</td>
<td>4.81</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.74</td>
<td>61.32</td>
<td>21.44</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>45.94</td>
<td>36.50</td>
<td>16.01</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>25.26</td>
<td>5.62</td>
<td>4.74</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>38.37</td>
<td>6.20</td>
<td>5.03</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.92</td>
<td>5.67</td>
<td>4.94</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>30.80</td>
<td>1.78</td>
<td>2.74</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>14.71</td>
<td>4.71</td>
<td>1.91</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>38.09</td>
<td>17.72</td>
<td>10</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.38</td>
<td>0.85</td>
<td>1.50</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>20.07</td>
<td>3.78</td>
<td>3.87</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.57</td>
<td>1.80</td>
<td>1.96</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>5.38</td>
<td>37.33</td>
<td>0.85</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>34.04</td>
<td>6.74</td>
<td>7.48</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>18.01</td>
<td>2.17</td>
<td>3.32</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>33.66</td>
<td>13.73</td>
<td>6.13</td>
<td>21.87%</td>
<td>$33.82</td>
<td>$70.57</td>
<td>13.06%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>When closely examining Merck &amp; Co, the following trends emerge: 
<ul>
<li>
A Price to Earnings ratio of 21.84 significantly below the industry average by 0.65x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
Considering a Price to Book ratio of 6.86, which is well below the industry average by 0.5x, the stock may be undervalued based on its book value compared to its peers.
</li>
<li>
With a relatively low Price to Sales ratio of 4.81, which is 0.78x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 13.0%, which is 8.87% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.45 Billion, which is 0.22x below the industry average, the company may face lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $12.37 Billion, which indicates 0.18x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 7.16% is significantly lower compared to the industry average of 13.06%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726585251_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When examining Merck &amp; Co in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:
<ul>
<li>
Merck &amp; Co is in a relatively stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.87.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity.
</li>
</ul>
<h3>Key Takeaways</h3>
For Merck &amp; Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest weaker financial performance relative to industry competitors. This may reflect challenges in generating profits and growth for Merck &amp; Co within the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Competitor Analysis: Evaluating Merck &amp; Co And Competitors In Pharmaceuticals Industry

Tuesday, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) released topline data from the&nbsp;HERTHENA-Lung02&nbsp;phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic&nbsp;EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40893317/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression-free-survi" rel="noreferrer noopener">inhibitor (TKI) treatment</a>.
The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs" rel="noreferrer noopener">Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs</a>.
Overall survival (OS) data were immature at the time of the analysis, and the trial will continue to assess OS, a secondary endpoint.
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) and being jointly developed by Daiichi Sankyo and Merck.
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.
The majority of interstitial lung disease (ILD) events were low-grade (grades 1 and 2). Two grade 5 ILD events were observed.
Recently,&nbsp;Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)&nbsp;released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China,&nbsp;sponsored by collaboration&nbsp;partner&nbsp;Akeso, Inc.
The trial evaluated monotherapy ivonescimab against Merck&#8217;s Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40771038/summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-ris" rel="noreferrer noopener">positive PD-L1 expression</a>.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial&#8217;s primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51.
Price Action: MRK stock is up 0.39% at $118.42 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40895062/essilorluxottica-and-meta-platforms-double-down-on-smart-eyewear-details" target="_blank" rel="noreferrer noopener">EssilorLuxottica And Meta Platforms Double Down On Smart Eyewear: Details</a>.</li>
</ul>

DSNKY

SMMT

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

The&nbsp;HERTHENA-Lung02&nbsp;phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastaticEGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Overall survival (OS) data were immature at the time of the analysis and the trial will continue to further assess OS, a secondary endpoint.

Daiichi Sankyo And Merck Report Patritumab Deruxtecan Showed Statistically Significant Progression-Free Survival Improvement In EGFR-Mutated Non-Small Cell Lung Cancer Population

Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting

Merck fails in late-stage trial for Keytruda combo in colon cancer

Wall Street Lunch: China-Linked Hackers Get Access To Some U.S. Providers

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK – Research Report) and Omnicell (OMCL – Rese...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK) and Omnicell (OMCL)

In a report released today, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $...

Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)

Evaxion stock jumps on expanded vaccine development pact with MSD

Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use

Summit Therapeutics downgraded at Citi on valuation

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read more… The growing number of elderly people worldwide is fueling a surge in demand for healthcare services, pharmaceuticals, and insurance, giving the healthcare sector a significant tailwind. Additionally, with technological advancements and innovative treatments on the rise, the future of the industry looks brighter than ever.
Amid this backdrop, investors looking to invest in the healthcare sector could keep an eye on fundamentally strong companies like Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), which are well-positioned to capitalize on this demographic shift.
According to a report, one in five Americans will be 65 or older by 2040, reaching a <a href="https://www.urban.org/policy-centers/cross-center-initiatives/program-retirement-policy/projects/data-warehouse/what-future-holds/us-population-aging">total of 80 million</a>. As the global population ages, the need for biopharma products and modern, effective drugs to manage long-term diseases is poised to increase more than ever. The pharmaceuticals market is forecasted to generate $1.45 trillion in revenue by 2029, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">exhibiting a CAGR of 4.7%</a>.
Additionally, the health insurance sector, particularly those offering Medicare-related products and services, is poised to capitalize on this trend. As per Precedence Research, the global health insurance market is anticipated to hit $5.12 trillion by 2034, growing at a <a href="https://precedenceresearch.com/health-insurance-market">CAGR of 7.4%</a>.
Considering these conducive trends, let's look at the fundamentals of the above-mentioned stocks in detail:
Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>)
LLY is a medicine company that discovers, develops, manufactures, and markets human pharmaceuticals worldwide. The company offers medicines for diabetes, obesity, rheumatoid arthritis, plaque psoriasis, ulcerative colitis, depressive disorder, and others, in addition to oncology products.
On September 24, LLY announced that the Ministry of Health, Labour and Welfare of Japan approved Kisunla for treating adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) and those with mild dementia stage of AD. This treatment will help reduce the infusion burden for eligible patients.  
On September 13, LLY received approval from the U.S. Food and Drug Administration (FDA) for EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor. This biologic treatment is intended for adults and children aged 12 years and above with moderate-to-severe atopic dermatitis that is not well controlled with topical therapies. It aims to provide long-lasting efficacy to patients with a maintenance dose administered once a month for a year.
For the second quarter (ended June 30, 2024), LLY reported revenue of $11.30 billion, representing a 36% growth from the prior-year quarter. It reported a non-GAAP gross profit of $9.27 billion, indicating a 39.8% growth from the prior year quarter with a margin of 80.8% (up 250 bps year-over-year).
In addition, its operating income increased 74.8% year-over-year to $3.71 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $3.54 billion and $3.92 per share, up 85.9% and 85.8% year-over-year, respectively.
The company has updated its fiscal year 2024 guidance, increasing its revenue projection by $3 billion to a range of $45.40 billion to $46.60 billion. LLY's EPS is anticipated to fall between $15.10 and $15.60. On a consolidated adjusted basis, its non-GAAP EPS is expected to range from $16.10 to $16.60.
Street expects LLY's revenue for the fiscal third quarter (ending September 2024) to increase 26.5% year-over-year to $12.01 billion. Its EPS for the current quarter is expected to improve substantially from the year-ago value to $4.50. Moreover, it beat the EPS estimates in each of the trailing four quarters, which is promising.
Shares of LLY have surged 65.3% over the past year and 59.3% over the past nine months to close the last trading session at $909.32.
LLY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LLY has an A grade for Sentiment and a B for Growth. It is ranked #37 out of 157 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to see the additional ratings for LLY (Value, Momentum, Stability, and Quality).
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified health care company. The company operates through four segments: UnitedHealthcare; Optum Health; Optum Insight; and Optum Rx.
On September 17, the UNH Community Plan of New Mexico announced a collaboration with the school-based healthcare provider Goodside Health to provide and expand integrated physical and behavioral healthcare services to 50 New Mexico schools, with an investment of $250,000. This collaboration will help school children gain healthier access to primary care as well as mental health care.
On August 29, UNH announced a three-year strategic partnership with Goodwill Industries International, involving a $4.5 million investment, to increase access to education and training, support health-related social needs, and create workforce development opportunities. This partnership aims to help people overcome barriers that prevent them from obtaining employment and to create opportunities for job seekers.
In the fiscal second quarter that ended on June 30, 2024, UNH's total revenue increased 6.4% year-over-year to $98.86 billion. The company's adjusted net earnings came in at $6.31 billion, up 9.3% year-over-year, while its adjusted EPS grew 10.7% from the year-ago value to $6.80.
According to the financial guidance for fiscal year 2024, the company's adjusted earnings per share is anticipated to range from $27.50 to $28.
The consensus revenue estimate of $99.28 billion for the fiscal third quarter (ending September 2024) represents a 7.5% increase year-over-year. The consensus EPS estimate of $7.06 for the same quarter indicates a 7.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has surged 18.8% over the past three months to close the last trading session at $574.81.
UNH's mixed fundamentals are reflected in its POWR Ratings. The stock has a B grade for Stability and Sentiment. It is ranked #5 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
Beyond what is stated above, we've also rated UNH for Growth, Value, Momentum, and Quality. Get all UNH's ratings <a href="https://stocknews.com/stock/UNH/">here</a>.
Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global health care company offering health solutions through its prescription medicines, including biological therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On September 25, MRK received new approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for KEYTRUDA's significant role as a combination therapy and as a monotherapy for certain patients with urothelial carcinoma.
On September 18, MRK announced that the U.S. Food and Drug Administration (FDA) approved KEYTRUDA in combination with pemetrexed and platinum chemotherapy as a first-line treatment option for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
MRK's sales for the second quarter ended June 30, 2024, increased 7.2% year-over-year to $16.11 billion, while its KEYTRUDA product sales improved by 15.9% from the year-ago value to $7.27 billion. The company's non-GAAP net income stood at $5.81 billion compared to the prior-year quarter's loss of $5.22 billion, while its non-GAAP EPS came in at $2.28 versus a loss of $2.06 per share last year.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.40 billion to $64.40 billion, an increase from the previous guidance of $63.10 billion to $64.30 billion. The company also expects non-GAAP EPS to be between $7.94 and $8.04.
Analysts expect MRK's revenue for the fourth quarter (ending December 2024) to increase 7.1% year-over-year to $15.67 billion, while its EPS for the same period is expected to grow significantly from the prior year to $1.91. Moreover, the company topped the consensus revenue estimates in each of the trailing four quarters.
Over the past year, the stock has gained 7.3%, closing the last trading session at $113.09.
MRK's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Value and Stability. Within the Medical - Pharmaceuticals industry, it is ranked #7 out of 157 stocks. <a href="https://stocknews.com/stock/MRK/">Click here</a> to see MRK's ratings for Growth, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $884.11 per share on Friday morning, down $25.21 (-2.77%). Year-to-date, LLY has gained 52.41%, versus a 21.84% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lly-unh-mrk-3-healthcare-stocks-to-watch-as-the-aging-population-drives/>3 Healthcare Stocks to Watch as the Aging Population Drives Demand</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

Merck snaps six straight sessions of losses

AKESF

KLAC

LCID

OKTA

OMCL

PHIN

RIVN

UBER

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

Merck's KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

GLMD

NVCT

ONCY

TSX:ONC

TYO:4568

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Merck & Co

Vendite allo scoperto

Merck & Co (NYSE:MRK) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO